Impact of Shingles Vaccine on Dementia Risk

Study Overview

In a July 2024 article in Nature Medicine, researchers from Oxford University revealed a significant finding: receiving the shingles vaccine may lower the risk of developing dementia in later life. This update is based on an extensive analysis of medical records from over a quarter million American seniors.

Research Findings

The study examined health outcomes of individuals aged 65 and older who received the shingles vaccine between 2017 and 2020. The researchers discovered that, on average, vaccinated seniors delayed the onset of various types of dementia (excluding frontotemporal and Lewy body dementia) by as much as 164 days. This translates to a 17% longer period before a dementia diagnosis, with the findings holding true for both men and women.

Understanding Averages and Variability

It is crucial to interpret these results carefully, as averages can obscure larger individual effects. The data was based on 103,837 vaccinated individuals compared to an equal number of unvaccinated individuals. Some participants in both groups may never develop dementia, which could diminish the observed differences. Notably, similar outcomes have been reported in studies involving Alzheimer’s treatments, suggesting that the shingles vaccine’s effect could be even more pronounced for certain individuals.

Exploring Potential Explanations

Given the surprising nature of these findings, the researchers investigated various factors that might explain the differences. They considered whether the vaccinated group experienced early mortality that could preclude dementia diagnosis and examined the potential impact of COVID-19 on diagnosis timing.

Another factor assessed was whether general health consciousness among vaccinated individuals contributed to the findings. The researchers explored if individuals close to a dementia diagnosis might be less proactive about health care appointments. Interestingly, when comparing vaccinated seniors with those who received only flu or Tdap vaccines, the delay in dementia diagnosis remained consistent, although the hazard ratio was small.

Vaccine Type and Effectiveness

The type of shingles vaccine administered did not significantly affect the rate of dementia delay. The protective effect appeared to be linked to preventing the varicella-zoster virus from becoming active.

The Varicella-Zoster Virus Connection

The varicella-zoster virus, responsible for both chickenpox and shingles, can remain dormant in the body after an initial chickenpox infection. Once the immune system has cleared the initial infection, some viral particles may hide in nerve cells, evading immune detection. While some individuals remain asymptomatic, others may develop shingles, characterized by a painful rash that follows nerve pathways.

Importance of Vaccination

Vaccinating children against chickenpox not only protects them from the illness but also reduces their risk of developing shingles later in life. For adults who had chickenpox, receiving the shingles vaccine is an effective way to prevent outbreaks.

Concluding Thoughts

While further research is needed to confirm the connection between the shingles vaccine and delayed cognitive decline, preventing shingles remains a beneficial health strategy.

Reference

Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med. Published online July 25, 2024:1-5. doi:10.1038/s41591-024-03201-5